We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+41.47%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$4.2B
AUM Growth
+$1.6B
Cap. Flow
+$825M
Cap. Flow %
19.63%
Top 10 Hldgs %
44.15%
Holding
117
New
24
Increased
10
Reduced
49
Closed
12

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$207M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$150M
3
BCAB icon
BioAtla
BCAB
+$76.6M
4
CCCC icon
C4 Therapeutics
CCCC
+$72.2M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$48.8M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$61.3M
2
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$50.2M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$35.5M
4
TWST icon
Twist Bioscience
TWST
+$30.5M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 78.9%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CEREW
101
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$753K 0.02%
+133,331
New +$538K
IMV
102
DELISTED
IMV Inc. Common Shares
IMV
$716K 0.02%
+23,437
New +$815K
NKTR icon
103
Nektar Therapeutics
NKTR
$2.58B
$680K 0.02%
2,667
-666
-20% -$172K
XFOR icon
104
X4 Pharmaceuticals
XFOR
$460M
$669K 0.02%
+3,466
New +$681K
NERV icon
105
Minerva Neurosciences
NERV
$199M
$468K 0.01%
25,000
-4,852
-16% -$122K
AMRN
106
Amarin Corp
AMRN
$303M
– –
-15,000
Closed -$1.26M
ARCT icon
107
Arcturus Therapeutics
ARCT
$211M
– –
-700,000
Closed -$30M
LKFT
108
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
– –
-130,000
Closed -$18.5M
KZR
109
DELISTED
Kezar Life Sciences
KZR
– –
-93,180
Closed -$4.51M
QTTB icon
110
Q32 Bio
QTTB
$464M
– –
-26,161
Closed -$5.04M
SRNE
111
CALL
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-500,000
Closed -$5.58M
CCXI
112
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-250,000
Closed -$13.7M
OTLKW
113
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
– –
-416,666
Closed -$54K
TRIL
114
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-2,500,000
Closed -$35.5M
EIDX
115
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-993,185
Closed -$50.2M
MYOK
116
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-450,000
Closed -$61.3M
AVEO
117
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-1,000,000
Closed -$5.94M
1 2 3 4
5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Cormorant Asset Management held 117 positions worth $4.2B, up 62% from $2.6B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management deployed $825M of net new capital in Q4 2020, opening 24 new positions and adding to 10 existing holdings. Its largest new stake was Atea Pharmaceuticals: 6,411,355 shares worth $260M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Twist Bioscience, an estimated $30.5M trimmed.

  • Cormorant Asset Management's largest Q4 2020 buy was Atea Pharmaceuticals: 6,411,355 shares worth $260M.
  • Cormorant Asset Management added most to Forma Therapeutics Holdings, Inc. Common Stock in Q4 2020, an estimated $47M increase.
  • Cormorant Asset Management's biggest Q4 2020 reduction was Twist Bioscience, cutting an estimated $30.5M.
  • Cormorant Asset Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $61.3M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $4.2B portfolio in Q4 2020.
  • Cormorant Asset Management opened 24 new positions and closed 12 in Q4 2020.
  • Cormorant Asset Management's portfolio value rose 62% quarter-over-quarter to $4.2B.

Based on Cormorant Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.